On March 23, Wuxi Apptec Co.Ltd(603259) disclosed the 2021 annual report. During the reporting period, the operating revenue was 22.902 billion yuan, a year-on-year increase of 38.5%; The net profit attributable to the parent company was 5.097 billion yuan, a year-on-year increase of 72.19%; Net profit deducted from non parent company was RMB 4.064 billion, with a year-on-year increase of 70.38%. The basic earnings per share is 1.75 yuan. The company plans to distribute a cash dividend of 5.174 yuan (including tax) for every 10 shares.
In 2021, the company’s chemical business realized a revenue of 14.087 billion yuan, a year-on-year increase of 46.93%; The revenue from testing business was 4.525 billion yuan, a year-on-year increase of 38.03%; The biological business realized a revenue of 1.985 billion yuan, a year-on-year increase of 30.05%; Ctdmo business of cell and gene therapy realized a revenue of 1.026 billion yuan, a year-on-year decrease of 2.79%; China’s new drug R & D Service Department achieved a revenue of 1.251 billion yuan, a year-on-year increase of 17.47%.
During the reporting period, the company achieved a gross profit of 8.31 billion yuan, an increase of 32.28% over the same period in 2020; The gross profit margin of the main business was 36.27%, down 1.7% from the same period of last year, mainly due to the negative impact on the company’s revenue and gross profit caused by the sharp depreciation of the US dollar against the RMB in 2021; The price rise of raw materials caused by the price rise of bulk materials; The impact of the exemption of social security expenses during the epidemic period in China last year.
During the reporting period, the company’s R & D expenditure was 942 million yuan, an increase of 35.91% over 2020. The company is committed to improving R & D capability, continuously increasing R & D investment, and focusing on the construction of platform empowerment, including enzyme catalysis, flow chemistry, etc. It also focuses on a series of new capacity-building R & D activities such as Tessa, protac, oligonucleotide drugs, polypeptide drugs, coupling drugs, cell and gene therapy and resource sequencing algorithm development.
